First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial-Reference-Cited by-同舟云学术

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial

Published:2014-09 Issue:13 Volume:50 Page:2219-2230
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Yang James Chih-Hsin,Kang Jin Hyoung,Mok Tony,Ahn Myung-Ju,Srimuninnimit Vichien,Lin Chia-Chi,Kim Dong-Wan,Tsai Chun-Ming,Barraclough Helen,Altug Sedat,Orlando Mauro,Park Keunchil

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference29 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer,2010

2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 2. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf; 2013 [accessed 22.08.13].

3. Focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer;Azzoli;J Clin Oncol,2011

4. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;D’Addario;Ann Oncol,2010

5. Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials;Li;PLoS One,2012

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials;Expert Review of Anticancer Therapy;2024-06-03

2. Multi‐state network meta‐analysis of progression and survival data;Statistics in Medicine;2023-06-10

3. Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR‐TKIs in advanced non‐small cell lung cancer: A systematic review and network meta‐analysis;Thoracic Cancer;2023-01-02

4. Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis;Clinics;2023-01

5. The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials;PLOS ONE;2022-10-10